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OBJECTIVES We investigated whether impaired platelet-derived nitric oxide (PDNO) bioactivity and
augmented platelet aggregability in chronic smokers are related to the imbalance of the
intraplatelet redox state through increased oxidative stress.
BACKGROUND Chronic smoking impairs PDNO release and augments platelet aggregability. However, their
mechanisms are unknown.
METHODS Collagen-induced PDNO release, platelet aggregation, plasma and intraplatelet vitamin C
and reduced glutathione (GSH), intraplatelet cyclic guanosine 3,5-monophosphate
(cGMP) and intraplatelet nitrotyrosine production, which is a marker of the peroxynitrite
formation, were measured in 11 chronic smokers and 10 age-matched nonsmokers.
RESULTS Release of PDNO and levels of intraplatelet cGMP were lower, and platelet aggregation was
greater, in smokers than in nonsmokers. Intraplatelet vitamin C and GSH levels were lower
in smokers than in nonsmokers. Intraplatelet nitrotyrosine production was greater in smokers
than in nonsmokers. Next, we investigated the effects of oral vitamin C administration (2 g).
After vitamin C administration, intraplatelet vitamin C levels were increased and not different
at 2 h between the two groups. Then, PDNO release, intraplatelet cGMP levels and platelet
aggregation in smokers were restored to the levels of nonsmokers. In smokers, PDNO release
and consumption of GSH during platelet aggregation were inversely correlated, and
consumption was much less after vitamin C administration. Vitamin C administration
decreased intraplatelet nitrotyrosine production in smokers.
CONCLUSIONS Impaired PDNO bioactivity and augmented platelet aggregability may be caused by an
imbalance of the intraplatelet redox state through increased oxidative stress in smokers. (J
Am Coll Cardiol 2001;38:1320–7) © 2001 by the American College of Cardiology
Platelets possess the L-arginine–nitric oxide (NO) pathway
through constitutive NO synthase (NOS) in human plate-
lets (1,2). Platelet aggregation is inhibited by L-arginine, a
precursor of NO, and potentiated by NG-monomethyl-L-
arginine (L-NMMA), an inhibitor of NOS (1,3). Platelet
aggregation is accompanied by an increase in the intracel-
lular level of cyclic guanosine 3,5-monophosphate
(cGMP) (1,3). These findings indicate evidence of the
functional L-arginine–NO pathway in platelets during ag-
gregation, which acts as a negative feedback mechanism to
inhibit not only platelet activation (4) but also recruitment
after aggregation (5). Recently, it has been shown that
impaired platelet-derived NO (PDNO) production may
contribute to the pathophysiology of acute coronary syn-
dromes (6).
Chronic smoking is a powerful risk factor for the devel-
opment of atherothrombosis (7). Recently, using an NO-
selective electrode, we directly measured PDNO bioactivity
during platelet aggregation (3). The bioactivity of PDNO
was impaired in chronic smokers (3), although the mecha-
nisms were not fully elucidated. Thus, in chronic smokers,
production or release of PDNO may be impaired, or
inactivation of PDNO may be augmented. There have been
several reports suggesting that smoking-related oxidative
stress may inactivate NO and play a role in the impaired
endothelium-dependent vasodilation in chronic smokers
(8,9). Another possibility is that the disturbed intracellular
redox state brought on by chronic smoking modulates the
action and metabolism of NO (10,11). However, it is
impossible to evaluate the intracellular redox state of the
endothelium in vivo. In this study, to investigate the
contribution of the redox state to impaired PDNO bioac-
tivity in chronic smokers, we investigated not only PDNO
release, but also the intraplatelet redox state by measuring
intraplatelet vitamin C, reduced glutathione (GSH) and
intraplatelet nitrotyrosine production.
Vitamin C and GSH are the main water-soluble, low-
molecular-weight antioxidants that directly scavenge oxygen
free radicals (12–14). Vitamin C plays a central role in the
regulation of the intracellular redox state by interacting with
GSH (13,14), which modulates the action of NO (10,11).
Moreover, vitamin C can replace GSH, and vice versa, as
intracellular antioxidants (15). In this study, we found lower
levels of intraplatelet vitamin C and GSH in chronic
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smokers, suggesting that the imbalance of the intraplatelet
redox state causes impaired bioactivity of PDNO. Accord-
ingly, we examined the effects of oral administration of 2 g
of vitamin C on PDNO bioactivity, platelet aggregation, the
intraplatelet redox state and intraplatelet nitrotyrosine pro-
duction.
METHODS
Study groups. The study groups consisted of 11 male
smokers who smoked at least 15 cigarettes/day for more
than five years and 10 healthy, age-matched male nonsmok-
ers who never smoked (Table 1). They had no evidence of
other major risk factors, including hypercholesterolemia,
hypertension and diabetes mellitus. Smokers had abstained
from smoking for at least 120 min before initiating the
protocol to avoid the acute effects of smoking on platelet
function. The protocols were approved by the institutional
Ethic Committees, and written, informed consent was
obtained from all subjects.
Preparation of platelet-rich plasma and washed platelets.
Platelet suspensions were prepared as described previously
(3,16). The platelet counts were adjusted to 1–2  105
platelets/l in Tyrode’s solution, the composition of which
was described previously (3).
Measurement of the electrical current with an NO-
specific electrode. Measurements of NO were performed
using an NO meter (Model N0-501, Inter Medical Co.,
Tokyo, Japan), as described previously (3). After the base-
line electric current was stabilized, a collagen-induced (3
g/ml) electrical current was recorded at the rate of 20
mm/min, and a change in the peak electrical current was
considered as an index of the NO release.
Measurement of intraplatelet cGMP levels. We mea-
sured intraplatelet cGMP levels after collagen-induced (3
g/ml) platelet aggregation by using a radioimmunoassay
kit (Yamasa Shoyu Co., Chiba, Japan), as described previ-
ously (3). The changes in the intraplatelet cGMP levels
were expressed by subtracting the levels in the absence of
collagen from the levels in the presence of collagen.
Measurement of platelet aggregation. We measured
collagen-induced platelet aggregation, as described previ-
ously (3). In brief, collagen (1, 3 or 5 g/ml) was added to
the washed platelet suspensions, and light transmission was
monitored by using a platelet aggregometer (MDM He-
matracer, MC Medical Co., Tokyo, Japan).
Measurement of plasma and intraplatelet antioxidants.
We measured plasma and intraplatelet antioxidants, includ-
ing vitamin C and GSH, by high-performance liquid
chromatography with an electrochemical detection system
(ECD-300, Eicom Co., Kyoto, Japan), as described previ-
ously (17). Deproteinized samples were used for injection.
Intraplatelet levels of antioxidants were determined by
subtracting the levels of platelet-poor plasma from those of
platelet-rich plasma and were measured before and after the
collagen-induced (3 g/ml) aggregation. Then, consump-
tion of the intraplatelet antioxidants by aggregation was
determined by subtracting the levels of antioxidants after
aggregation from those before aggregation. Furthermore,
we estimated the mean platelet volume by using an elec-
tronic particle volume analyzer (SE9000 Sysmex Co., Kobe,
Japan) and then calculated intraplatelet concentrations
(mmol/l) of vitamin C.
Detection of intraplatelet nitrotyrosine. We measured
intraplatelet nitrotyrosine production by using a modified
method of a previous study (18). Immuno-labeling was per-
formed by using a polyclonal antibody to nitrotyrosine as a
primary antibody and fluorescein isothiocyanate-conjugated
goat anti-rabbit immunoglobulin G (IgG) as a secondary
antibody, and then analyzed with the FACScan (Becton-
Deckinson, San Diego, California). The results were expressed
as the percent changes in nitrotyrosine-specific staining of
platelets by collagen-induced platelet aggregation in each
group. Platelets from smokers (n  5) were stimulated by
collagen in the presence of either NG-nitro-L-arginine meth-
ylester (L-NAME; 300 mol/l), an inhibitor of NOS, or
4,5-dihydroxy-1,3-benzene disulfonic acid (Tiron; 1 mmol/l),
an intracellular scavenger of superoxide anion. L-NAME and
Tiron completely inhibited the production of intraplatelet
nitrotyrosine, indicating that nitrotyrosine is really a “footprint”
of peroxynitrite, resulting from the interaction between NO
and superoxide anion.
Abbreviations and Acronyms
cGMP  cyclic guanosine 3,5-monophosphate
GSH  reduced glutathione
IgG  immunoglobulin G
L-NAME  NG-nitro-L-arginine methylester
L-NMMA  NG-monomethyl-L-arginine
NO  nitric oxide
NOS  nitric oxide synthase
PDNO  platelet-derived nitric oxide
Table 1. Baseline Characteristics
Nonsmokers Smokers
p
Value
Age (years) 32  1 34  1 NS
Male/female 10/0 11/0 NS
Cigaretts per day 0 27  2 —
Smoking period (years) 0 15.2  1 —
Systolic/diastolic blood
pressure (mm Hg)
120  4/73  3 123  4/76  2 NS
Heart rate (beats/min) 68  3 66  2 NS
Total cholesterol (mg/dl) 182  3 189  5 NS
HDL cholesterol (mg/dl) 53  4 55  6 NS
LDL cholesterol (mg/dl) 102  3 99  3 NS
Fasting blood sugar (mg/dl) 85  2 87  3 NS
Platelet count (104/l) 23  1 22  1 NS
Fibrinogen (mg/dl) 262  23 288  25 NS
Prothrombin time (%) 102  3 108  3 NS
Plasma epinephrine (pg/ml) 38  3 47  3 NS
Plasma norepinephrine (pg/ml) 409  45 442  54 NS
Nicotine (ng/ml) Not detectable 7.2  0.6 —
Data are expressed as the mean value  SE.
HDL and LDL  high and low density lipoprotein, respectively.
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Effects of vitamin C administration. In all subjects, we
administered 2 g of vitamin C orally, and plasma and
intraplatelet vitamin C levels were measured every 30 min
for 3 h. Measurements of the platelet-derived electrical
current, intraplatelet cGMP, platelet aggregation and GSH
were repeated 2 h after vitamin C administration.
Statistical analysis. Data are presented as the mean
value  SEM. Statistical comparisons between the groups
were performed by using the paired or unpaired Student t test.
Two-way repeated measures analysis of variance was used to
determine the effects of smoking and the time to effect after
vitamin C administration on plasma and intraplatelet vitamin
C concentrations. The relationship between two variables was
analyzed by use of linear regression analysis. Differences were
considered statistically significant at p  0.05.
RESULTS
Platelet-derived electrical currents, intraplatelet cGMP
levels and platelet aggregation. Electrical currents (Fig.
1A) and intraplatelet cGMP (Fig. 1B) levels were signifi-
cantly lower, and platelet aggregation (Fig. 1C) was signif-
icantly greater in smokers.
Effects of vitamin C administration on platelet-derived
electrical currents, intraplatelet cGMP levels and plate-
let aggregation. After vitamin C administration, electrical
currents and intraplatelet cGMP levels were significantly
increased in nonsmokers and smokers. These values were no
longer different between the two groups (Fig. 1A and 1B).
Vitamin C administration inhibited platelet aggregation in
smokers, and platelet aggregation was no longer different
between the two groups (Fig. 1D).
Plasma and intraplatelet antioxidants. Before vitamin C
administration, plasma (Fig. 2A) and intraplatelet (Fig. 2B)
vitamin C levels and intraplatelet GSH levels (Fig. 2C) were
significantly lower in smokers than in nonsmokers. After
vitamin C administration, both plasma and intraplatelet
vitamin C levels were significantly increased, peaking at 2 h
in both nonsmokers and smokers (Fig. 2A and 2B). The
peak value of intraplatelet vitamin C was no longer different
between the two groups (Fig. 2B). Vitamin C administra-
tion did not change intraplatelet GSH levels in either group
(Fig. 2C).
Consumption of intraplatelet vitamin C and GSH before
and after vitamin C administration. Before vitamin C
administration, consumption of intraplatelet vitamin C and
GSH during platelet aggregation did not differ between
smokers and nonsmokers (Fig. 3A and 3B). After vitamin C
administration, consumption of intraplatelet vitamin C was
significantly increased in both groups and were not different
between the two groups (Fig. 3A). After vitamin C admin-
istration, although the consumption of intraplatelet GSH
was not changed in nonsmokers, it was significantly de-
Figure 1. Collagen-induced platelet-derived electrical currents (A) and intraplatelet cyclic guanosine 3,5-monophosphate (cGMP) levels (B) before and
after vitamin C administration in nonsmokers (n  10) and smokers (n  11). Collagen-induced platelet aggregation before (C) and after (D) vitamin C
administration in nonsmokers (n  10) and smokers (n  11). Open bars  nonsmokers; solid bars  smokers; NS  nonsignificant.
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creased in smokers. Consequently, consumption of GSH
during platelet aggregation in smokers was much less after
than before vitamin C administration (Fig. 3B).
Relationship between consumption of intraplatelet GSH
and platelet-derived electrical currents. In smokers, the
collagen-induced, platelet-derived electrical current exhib-
ited a significant inverse correlation with the consumption
of intraplatelet GSH by platelet aggregation before (r 
0.64, p  0.05) and after (r  0.67, p  0.03) vitamin
C administration (Fig. 3D). No such relationship was found
in nonsmokers (Fig. 3C). Importantly, the line of in-
traplatelet GSH consumption and platelet-derived electrical
current was shifted upward after vitamin C administration
in smokers.
Intraplatelet nitrotyrosine production before and after
vitamin C administration. Figure 4 shows the representa-
tive histograms of intraplatelet nitrotyrosine production in a
nonsmoker and a smoker. Before vitamin C administration,
the percent change in intraplatelet nitrotyrosine production
was significantly higher in smokers than in nonsmokers.
This increased intraplatelet nitrotyrosine formation in
smokers was not observed when nonspecific IgG was
applied instead of the nitrotyrosine antibody, or when the
nitrotyrosine antibody was applied in the presence of excess
soluble nitrotyrosine (10 mmol/l). Vitamin C administra-
tion significantly decreased intraplatelet nitrotyrosine pro-
duction in smokers, and their levels were decreased to the
levels of nonsmokers (Fig. 4D).
DISCUSSION
The NO-selective electrode is specifically capable of mea-
suring NO release (3,19,20). We previously showed that
the electrode used in this study was sensitive enough to
detect NO release from aggregated platelets, on the basis of
the following findings (3). First, S-nitroso-N-acetyl-dl-
penicillamine, a direct NO donor, dose dependently in-
creased the electrical current. Second, the electrical current
showed a high correlation with collagen concentrations (r
0.94) used for platelet aggregation. Third, the collagen-
induced electrical current and intraplatelet cGMP levels
were increased by L-arginine and attenuated by L-NMMA.
Fourth, a good correlation was found between collagen-
induced intraplatelet cGMP and the electrical current (r 
0.73). Thus, we confirmed that the changes in the electrical
current reflect the amount of NO released through the
L-arginine–NO pathway in aggregated platelets.
In the present study, the baseline characteristics did not
differ between the two groups, except for plasma nicotine
levels (Table 1). Accordingly, it is likely that the present
observations of impaired PDNO bioactivity and augmented
platelet aggregability are exclusively related to chronic
Figure 2. Time courses of plasma (A) and intraplatelet (B) levels of vitamin C in nonsmokers (n  10; open circles) and smokers (n  11; solid circles).
*p  0.05 indicates the difference between nonsmokers and smokers before vitamin C administration. (C) Intraplatelet reduced glutathione (GSH) levels
before and after vitamin C administration in nonsmokers (n  10) and smokers (n  11). NS  nonsignificant.
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smoking. Thus, our previous and present findings indicate
that the L-arginine–NO pathway, as a negative feedback
mechanism of platelet aggregation, is impaired in chronic
smokers, resulting in increased platelet aggregability. How-
ever, the mechanisms of impaired PDNO bioactivity and
augmented platelet aggregability in chronic smokers were
unknown previously.
Oxidative stress in chronic smokers. A previous study
(21) and our studies indicate that smoking induces oxidative
stress, which is associated with decreased plasma vitamin C
levels. Moreover, we demonstrated for the first time, to the
best of our knowledge, that intraplatelet vitamin C levels
were significantly lower in smokers than in nonsmokers.
Because vitamin C is a potent antioxidant, one may consider
that vitamin C protects against free radical-mediated inac-
tivation of PDNO. Thus, our results may suggest that
oxidative stress associated with decreased intraplatelet vita-
min C is related to impaired bioactivity of PDNO in
chronic smokers.
In addition to vitamin C, intracellular GSH also serves as
a free radical scavenger (12,13). Furthermore, GSH not
only regulates the intracellular redox state, but also modu-
lates the action and metabolism of NO (10,11). It has also
been shown in cultured endothelial cells that depletion of
GSH decreases synthesis of NO (22) and that reduced thiol
enhances NO activity (23). These findings indicate that
intracellular GSH plays an important role in modulating the
action and metabolism of NO. Accordingly, we examined
the intraplatelet GSH level. It was confirmed, for the first
time, that the intraplatelet GSH level is significantly lower
in smokers. Taken together, our findings indicate that
smoking-related oxidative stress decreases not only plasma
vitamin C levels but also intraplatelet vitamin C and GSH
levels, resulting in an imbalance of the intraplatelet redox
state. To further address this issue, we measured intraplate-
let peroxynitrite production, a reaction product of superox-
ide anion and NO (24), which was significantly higher in
smokers. Based on these findings, we assumed that the
imbalance of the intraplatelet redox state is responsible for
the impaired PDNO release in chronic smokers. To further
test this hypothesis, we investigated whether modulation of
the intraplatelet redox state by vitamin C administration
affects PDNO release and platelet aggregation.
Effects of vitamin C administration. We determined the
time course of plasma and intraplatelet vitamin C levels
after oral administration of vitamin C (2 g). A similar dose
of vitamin C has been reported to improve endothelial
function in patients with coronary artery disease (25). Both
Figure 3. Consumption of intraplatelet vitamin C (A) and reduced glutathione (GSH) (B) by platelet aggregation before and after vitamin C administration
in nonsmokers (n  10) and smokers (n  11). Correlation between the collagen-induced platelet-derived electrical current and consumption of
intraplatelet GSH by platelet aggregation before and after vitamin C administration in (C) nonsmokers (n  10) and (D) smokers (n  11). NS 
nonsignificant.
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plasma and intraplatelet vitamin C levels peaked 2 h after
oral vitamin C administration in nonsmokers and smokers.
The peak value of intraplatelet vitamin C was no longer
different between the two groups. Therefore, we chose to
study 2 h after 2 g of oral vitamin C administration. Vitamin
C increased PDNO release and intracellular cGMP in
smokers and nonsmokers. These values were no longer
different between smokers and nonsmokers after vitamin C
administration, and enhanced platelet aggregability in
smokers was normalized. Thus, our results provide more
direct evidence that the imbalance of the intraplatelet redox
state is responsible for the impairment of PDNO release
and augmented platelet aggregability in chronic smokers.
There are several possible mechanisms of the antioxidant
effects of vitamin C on platelets. First, one may consider
that increased plasma vitamin C protected against free
radical–mediated inactivation of PDNO. In this study, the
plasma vitamin C level was increased from 28 (baseline
value) to 107 mol/l at 2 h. However, a recent in vitro study
by Jackson et al. (26) showed that impaired endothelium-
derived NO release by superoxide was not prevented by
vitamin C at concentrations 150 mol/l. Accordingly,
this possibility is unlikely. Second, it is possible that the
protective effects of vitamin C on PDNO release are
mediated by the antioxidant property of vitamin C at the
intraplatelet level. Jackson et al. (26) demonstrated that
vitamin C was effective in competing with NO for super-
oxide at concentrations 1 mmol/l. Thus, they speculated
that the vasorelaxing effects of exogenously administered
vitamin C on the constricted vascular strips by superoxide
were due to the intracellular increases in vitamin C, al-
though they did not measure intracellular vitamin C con-
centrations. In this study, we measured intraplatelet and
plasma vitamin C concentrations in smokers at 2 h after
vitamin C administration, which were 8.3 mmol/l and 107
mol/l, respectively. Thus, our findings indicate that in-
traplatelet vitamin C concentrations are higher in platelets
than in plasma and are sufficient enough to scavenge
superoxide anion. Third, the antioxidative effects of vitamin
C may have prevented oxidation of intraplatelet GSH,
resulting in the preservation of GSH levels. However,
vitamin C administration did not change intraplatelet GSH
levels in nonsmokers and smokers. The process of platelet
aggregation involves the generation of oxygen free radicals
(27), and intracellular antioxidants such as vitamin C and
GSH may be consumed during platelet aggregation. Ac-
cordingly, we calculated consumption of intracellular vita-
min C and GSH during platelet aggregation, and the
consumption rates were similar between the two groups
before vitamin C administration. After vitamin C adminis-
Figure 4. (A–C) Representative histograms of intraplatelet nitrotyrosine production in a nonsmoker and a smoker. In the smoker before vitamin C
administration, the fluorescent peak of nitrotyrosine in platelets stimulated by collagen (3 g/ml) (open area) shifted to the right from fluorescent peaks
of unstimulated platelets (solid area). In the smoker after vitamin C administration, the histograms were identical to those of the nonsmoker. (D)
Intraplatelet nitrotyrosine production by collagen-induced platelet aggregation in nonsmokers (n  8) and in smokers (n  8).
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tration, consumption of intraplatelet vitamin C was signif-
icantly increased in both nonsmokers and smokers, and,
again, no difference was found between the two groups.
However, consumption of intraplatelet GSH after vitamin
C administration was significantly lower in smokers than in
nonsmokers. These findings suggest that in smokers, vita-
min C may have preserved intraplatelet GSH during plate-
let aggregation.
To test this hypothesis, the correlation between PDNO
and the consumption of intraplatelet GSH by platelet
aggregation was evaluated. A significant and inverse corre-
lation was found in smokers but not in nonsmokers.
Furthermore, the curve was shifted upward after vitamin C
administration, indicating more PDNO release at the same
consumption of intraplatelet GSH. These findings suggest
that impaired PDNO bioactivity in smokers was restored by
intraplatelet GSH after vitamin C administration. Our data
support the notion that vitamin C spares GSH from
oxidation and preserves intracellular GSH levels under the
condition of increased oxidative stress (15), resulting in an
improved intracellular redox state (13). In this study, we
further examined whether improved PDNO bioactivity by
vitamin C administration in smokers was caused by the
antioxidant effects of vitamin C. This notion was supported
by evidence that vitamin C administration decreased in-
traplatelet nitrotyrosine production in smokers to the levels
of nonsmokers. Taken together, our findings suggest that in
smokers, vitamin C administration improves PDNO release
through the antioxidant effects of vitamin C.
Clinical implications. An important corollary to the redox
hypothesis of smoking-induced hyperaggregability found in
this study is the possibility that antioxidant treatment will
reduce atherothrombosis. However, in clinical trials (28,29),
antioxidant therapy with vitamin E in cardiovascular disease
did not consistently improve the outcome. A possible reason
for these disappointing results may be due to the lipophilic
property of vitamin E. In contrast to the hydrophilic
antioxidants, such as vitamin C, the effects of lipophilic
antioxidants may act on lipids, such as membranes and
cholesterol. Accordingly, vitamin C might be a better
antioxidant in terms of cellular redox modulation. There-
fore, the current results may encourage the endeavor of a
future, large, prospective study to test a long-term regimen
of vitamin C on cardiovascular morbidity and mortality.
Conclusions. Some previous studies have shown aug-
mented platelet aggregation in chronic smokers (30) and
beneficial effects of antioxidant therapy on platelet function
in humans (31,32). However, there is no report examining
the impact of antioxidant therapy on platelet function in
chronic smokers. The present study, to the best of our
knowledge, provides the first evidence that the imbalance of
the intraplatelet redox state caused by increased oxidative
stress may be an important mechanism for the impaired
PDNO bioactivity in chronic smokers. Accordingly, a
therapeutic strategy focusing on improvement of the intra-
cellular redox state may be considered in chronic smokers.
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